Publications:

Case Report: Favorable Response and Manageable Toxicity to the Combination of Camrelizumab, Oxaliplatin, and Oral S-1 in a Patient With Advanced Epstein-Barr Virus-Associated Gastric Cancer.

Frontiers In Oncology

Lv, Wanrui W; Cheng, Ke K; Li, Xiaofen X; Feng, Lusi L; Li, Hancong H; Li, Jia J; Chang, Chen C; Cao, Dan D

Publication Date: 2021

Variant appearance in text: TET2: 1634A>C

PubMed Link: 35096571

Variant Present in the following documents:

• fonc-11-759652.pdf

View BVdb publication page